CRISPR & CRISPR-associated Genes Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Global CRISPR and CRISPR-Associated (CAS) Genes Market is Segmented by Component (Product and Services), by Application (Biomedical, Agriculture and More), by End User (Biotechnology & Pharmaceutical Company and More), by Technology Type (CRISPR-Cas9 and More), by Delivery Method (Viral Vectors and Non-Viral) and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

CRISPR And CRISPR-associated (Cas) Genes Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of CRISPR And CRISPR-associated (Cas) Genes Market with other markets in Healthcare Industry

CRISPR And CRISPR-associated (Cas) Genes Market Analysis by Mordor Intelligence

The CRISPR market size reached USD 4.70 billion in 2025 and is forecast to rise to USD 8.95 billion by 2030, reflecting a 13.73% CAGR. The growth arc signals that gene editing has shifted from a specialized research tool toward a validated therapeutic and agricultural platform. Adoption has accelerated since the landmark late-2023 approval of Casgevy for sickle cell disease and beta thalassemia, which created a regulatory precedent and de-risked the clinical pathway for follow-on programs. Investment flows remain strong, supported by 14 FDA review designations granted to CRISPR therapies in 2023, an unusually high figure for a single modality. Agricultural use cases are scaling as the United States and select Asia-Pacific regulators exempt gene-edited crops that mimic conventional breeding, removing significant time and cost barriers. Technology refinement continues, with prime and base editing addressing off-target risks and AI-driven guide design cutting candidate selection cycles from months to weeks.

Key Report Takeaways

• By component, products led with 79.10% revenue share in 2024 while services are advancing at a 14.35% CAGR through 2030.

• By application, biomedical uses commanded 82.23% share of the CRISPR market size in 2024; agriculture is projected to expand at a 15.45% CAGR to 2030.

• By technology, CRISPR-Cas9 held 62.54% of CRISPR market share in 2024, whereas prime editing is forecast to grow at 16.01% CAGR.

• By end user, biotechnology and pharmaceutical firms captured 68.34% share in 2024; contract research and manufacturing organizations (CRO/CMO) record the fastest CAGR at 14.98%.

• By geography, North America accounted for 47.56% revenue in 2024 and Asia-Pacific is pacing at a 16.23% CAGR through 2030.

Segment Analysis

By Component – Products Drive Current Revenue

Products controlled 79.10% of total revenue in 2024, reflecting sustained demand for guide RNA kits, Cas enzymes, and transfection reagents used across discovery and translational workflows. Thermo Fisher and Merck KGaA offer catalogue reagents that scale with research throughput, underpinning a predictable revenue base that buffers volatility in therapeutic milestones. Services are pacing at a 14.35% CAGR as biotech clients outsource assay development, cell-line engineering, and GMP viral-vector production to specialist CROs. Charles River Laboratories positions itself as an end-to-end partner from discovery to Phase I manufacturing, mirroring a broader shift in the CRISPR market toward integrated external capabilities.

Growing therapeutic pipelines multiply demand for process development, quality control, and regulatory documentation, lifting service penetration every year of the forecast. Suppliers are bundling reagents, delivery vectors, and analytics software into platform packages to secure switching costs and capture a larger slice of downstream value.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Application – Biomedical Dominance Faces Agricultural Disruption

Biomedical programs generated 82.23% of 2024 revenue, sustained by high-value therapies, companion diagnostics, and drug discovery screens that command premium pricing and long-term partnerships. The implicit risk profile is balanced by strong venture capital support and expanding orphan-disease incentives. Agriculture, growing at 15.45% CAGR, benefits from streamlined regulation in the United States where gene-edited plants that could be derived through conventional breeding skip protracted environmental assessments, slashing the time to market and expanding farmer.

China’s 2025 guidance encouraging biotech cultivation of wheat, corn, and soy is set to unlock additional volume and reinforce the Asia-Pacific growth story. Synthetic biology use cases such as bio-production of specialty chemicals represent a nascent yet promising niche, though current revenue remains modest. Cross-fertilisation of knowledge between therapeutic and agricultural segments accelerates platform evolution, particularly around delivery vectors and computational design, deepening the overall CRISPR industry ecosystem.

By Technology – Prime Editing Challenges Cas9 Supremacy

CRISPR-Cas9 retained 62.54% share in 2024, anchored by extensive validation data and established manufacturing know-how that simplifies regulatory interactions. The CRISPR market now prizes precision; prime editing is achieving a 16.01% CAGR because it edits without double-strand breaks, alleviating safety hurdles that plague nuclease-based systems. Base editing occupies a middle ground, combining improved specificity with simpler reagent composition, and is moving into late-stage trials such as Beam’s BEAM-302 for alpha-1 antitrypsin deficiency beamtx.com. Novel Type I-D CRISPR systems from Japanese research groups illustrate ongoing diversification, with long guide RNAs that broaden accessible genomic regions and reduce off-target cuts.

Developers choose technologies based on tissue target, therapeutic index, and intellectual-property landscape rather than familiarity, so each platform must demonstrate unique value to secure share. The CRISPR market size attributable to prime editing therapies could expand significantly after PM359 human proof-of-concept, which would validate the platform for dozens of monogenic diseases.

By End User – CROs Capture Outsourcing Wave

Biotechnology and pharmaceutical companies generated 68.34% of 2024 revenue by advancing proprietary therapeutic candidates through in-house research, yet capacity constraints in manufacturing and analytics fuel outsourcing momentum. CROs and CDMOs are scaling faster than any other group at 14.98% CAGR as they absorb specialised tasks such as GMP vector production, in-vivo model generation, and regulatory dossier preparation. Academic institutes hold a steady share as foundational discovery engines but are also spinning out start-ups that later partner with industry for development resources.

The trend mirrors post-pandemic supply-chain recalibration in which companies reserve scarce internal talent for strategic decision-making while entrusting operational execution to partners with purpose-built capacity lek.com. Integrated service providers that can bundle design, build, test, and manufacture into a single workflow gain competitive advantage and deepen client lock-in, reinforcing consolidation within the service tier of the CRISPR market.

CRISPR & CAS Genes Market
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Delivery Method – Non-Viral Innovation Accelerates

AAV vectors dominate current approvals because decades of safety data reassure regulators and investors, yet their 4.7-kb payload ceiling constrains complex edits like prime or multiplex base editing[2]Source: Sangamo Therapeutics, “Proprietary AAV Capsid Data,” sangamo.com. Lipid nanoparticles sidestep size limits and immunogenicity but have historically struggled with tissue specificity; recent chemistry iterations now enable myocardium and central nervous system targeting, broadening the commercial scope wiley.com. Electroporation and nanoparticle carriers show promise for ex-vivo cell work, facilitating high edit rates with minimal cell toxicity.

Hybrid constructs merge capsid targeting with synthetic-carrier scalability, a configuration that large pharmas such as Regeneron are funding aggressively because it offers a path toward repeat dosing and broader tissue reach regeneron.com. Delivery modality will remain a key deciding factor for clinical success, meaning suppliers with robust vector IP can capture outsized value in the CRISPR market.

Geography Analysis

North America retained leadership with 47.56% revenue in 2024 thanks to FDA clarity, deep venture capital pools, and concentration of specialised talent in Boston and the San Francisco Bay Area. The region further benefits from USDA rules that treat certain gene-edited crops like conventionally bred varieties, supporting diversified revenue streams beyond therapeutics. Cost pressure and manufacturing bottlenecks create incentives for firms to establish production sites in lower-cost jurisdictions, slightly tempering growth yet maintaining strategic centrality through 2030.

Asia-Pacific posts the fastest CAGR at 16.23%, led by China’s strong state financing, a large talent base, and more than 700 active CRISPR clinical trials that now outnumber those in the United States. Policy initiatives like Japan’s Smart Cell Project aim to commercialise gene-engineered cellular factories for pharma and industrial applications, reinforcing a region-wide pivot to high-value biomanufacturing. India wrestles with restrictive licensing regimes that limit farmers’ adoption of CRISPR crops, underscoring the importance of intellectual-property frameworks in shaping local trajectories.

Europe holds significant scientific prowess but lags in commercialisation because gene-edited organisms fall under the same stringent rules as traditional GMOs, stretching approval timelines and raising compliance costs. Consequently many European firms conduct clinical trials in North America or Asia while maintaining R&D bases at home. Latin America, the Middle East, and Africa remain emergent; regulatory frameworks are still evolving and healthcare spending is lower, yet early adoption in Brazil’s agritech sector suggests future opportunity once global supply chains mature and local policy aligns with scientific progress.

CRISPR & CAS Genes Market
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

The CRISPR market is moderately fragmented; the top five pure-play developers together hold well under a quarter of total revenue, while tool suppliers and service platforms capture diverse niches. CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, and Beam Therapeutics each focus on differentiated technology stacks—ranging from allogeneic CAR-T cells to base and prime editing—and augment pipelines through large-pharma partnerships. Tool providers such as Thermo Fisher and Merck KGaA capitalise on early-stage demand but observe rising competition from start-ups offering integrated reagent-plus-software suites. Delivery specialists Mammoth Biosciences and Scribe Therapeutics occupy a critical chokepoint by supplying ultracompact Cas variants adaptable to diverse vectors.

Strategic moves in 2024-2025 show partnerships surpassing outright acquisitions in frequency as both sides prefer risk-sharing. Regeneron’s USD 370 million-per-target collaboration with Mammoth seeks to combine compact nucleases with proprietary lipid nanoparticles, exemplifying how delivery IP attracts investment. Vertex’s expanded alliance with CRISPR Therapeutics broadens focus from hematology into neuromuscular diseases, indicating that platform breadth is a coveted asset. Intellectual-property disputes linger in agriculture; broad patents held by academic consortia oblige emerging-market firms to license or partner to secure freedom to operate, as seen in India’s protracted negotiations on seed-trait licensing.

Looking ahead, competitive advantage will accrue to companies that can simultaneously master delivery, reduce manufacturing cost, and demonstrate long-term safety. Those outcomes require capital intensity and multidisciplinary expertise, implying that collaboration will remain the default pathway to scale within the CRISPR market.

CRISPR And CRISPR-associated (Cas) Genes Industry Leaders

  1. OriGene Technologies, Inc.

  2. Thermo Fisher Scientific

  3. Takara Bio Inc

  4. Addgene

  5. PerkinElmer Inc. (Horizon Discovery Ltd.)

  6. *Disclaimer: Major Players sorted in no particular order
CRISPR And CRISPR-associated (Cas) Genes Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • May 2025: CRISPR Therapeutics reported Phase 1 data for CTX310 showing triglyceride reductions up to 82% and held USD 1.86 billion in cash
  • May 2025: Sangamo Therapeutics priced a USD 23 million equity offering to fund neurology-focused AAV capsid programs
  • April 2025: Beam Therapeutics released new BEAM-302 data showing 91% corrected protein in alpha-1 antitrypsin deficiency patients

Table of Contents for CRISPR And CRISPR-associated (Cas) Genes Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 FDA approvals of CRISPR-based therapies
    • 4.2.2 Advances in delivery technologies (viral & non-viral)
    • 4.2.3 Rising R&D funding & strategic partnerships
    • 4.2.4 Mitochondrial in-vivo CRISPR opens rare-disease pipeline
    • 4.2.5 AI-driven sgRNA design accelerates time-to-lead
    • 4.2.6 Regulatory easing for gene-edited crops
  • 4.3 Market Restraints
    • 4.3.1 Off-target safety & ethical concerns
    • 4.3.2 High CMC & manufacturing cost structure
    • 4.3.3 Supply-chain concentration in Cas nucleases
    • 4.3.4 Public backlash over gene-drive ecology risk
  • 4.4 Value / Supply-Chain Analysis
  • 4.5 Regulatory Landscape
  • 4.6 Technological Outlook
  • 4.7 Porter’s Five Forces
    • 4.7.1 Threat of New Entrants
    • 4.7.2 Bargaining Power of Suppliers
    • 4.7.3 Bargaining Power of Buyers
    • 4.7.4 Threat of Substitutes
    • 4.7.5 Competitive Rivalry

5. Market Size & Growth Forecasts (Value)

  • 5.1 By Component
    • 5.1.1 Products
    • 5.1.2 Services
  • 5.2 By Application
    • 5.2.1 Biomedical
    • 5.2.2 Agriculture
    • 5.2.3 Industrial & Synthetic Biology
  • 5.3 By End User
    • 5.3.1 Biotechnology & Pharmaceutical Cos.
    • 5.3.2 Academic & Government Institutes
    • 5.3.3 Contract Research / Manufacturing Orgs.
  • 5.4 By Technology Type
    • 5.4.1 CRISPR-Cas9
    • 5.4.2 Base Editing
    • 5.4.3 Prime Editing
    • 5.4.4 CRISPR-Cas12/13 & Others
  • 5.5 By Delivery Method
    • 5.5.1 Viral Vectors
    • 5.5.2 Non-viral (LNPs, Electroporation, Nanocarriers)
  • 5.6 By Geography
    • 5.6.1 North America
    • 5.6.1.1 United States
    • 5.6.1.2 Canada
    • 5.6.1.3 Mexico
    • 5.6.2 Europe
    • 5.6.2.1 Germany
    • 5.6.2.2 United Kingdom
    • 5.6.2.3 France
    • 5.6.2.4 Italy
    • 5.6.2.5 Spain
    • 5.6.2.6 Rest of Europe
    • 5.6.3 Asia-Pacific
    • 5.6.3.1 China
    • 5.6.3.2 Japan
    • 5.6.3.3 India
    • 5.6.3.4 South Korea
    • 5.6.3.5 Australia
    • 5.6.3.6 Rest of Asia-Pacific
    • 5.6.4 Middle East and Africa
    • 5.6.4.1 GCC
    • 5.6.4.2 South Africa
    • 5.6.4.3 Rest of Middle East and Africa
    • 5.6.5 South America
    • 5.6.5.1 Brazil
    • 5.6.5.2 Argentina
    • 5.6.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
    • 6.3.1 CRISPR Therapeutics
    • 6.3.2 Editas Medicine
    • 6.3.3 Intellia Therapeutics
    • 6.3.4 Beam Therapeutics
    • 6.3.5 Caribou Biosciences
    • 6.3.6 Mammoth Biosciences
    • 6.3.7 Synthego
    • 6.3.8 Thermo Fisher Scientific
    • 6.3.9 Merck KGaA (Sigma-Aldrich)
    • 6.3.10 Agilent Technologies
    • 6.3.11 Horizon Discovery
    • 6.3.12 Origene Technologies
    • 6.3.13 Charles River Laboratories
    • 6.3.14 Sangamo Therapeutics
    • 6.3.15 ERS Genomics
    • 6.3.16 Aldevron
    • 6.3.17 Ubigene Biosciences
    • 6.3.18 Cellecta
    • 6.3.19 Applied StemCell
    • 6.3.20 Integrated DNA Technologies
    • 6.3.21 Verve Therapeutics

7. Market Opportunities & Future Outlook

  • 7.1 White-space & Unmet-Need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global CRISPR And CRISPR-associated (Cas) Genes Market Report Scope

As per the scope of the report, clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) Genes market, CRISPR-Cas9, which is an acronym for clustered regularly interspaced short palindromic repeats and CRISPR-associated protein 9 is a microbial adaptive immune system against viruses and plasmids, that gives scientists the ability to change an organism's DNA (genome editing).

The CRISPR and CRISPR-associated (Cas) genes market is segmented by product (vector-based cas and DNA-free cas), application (genome engineering, disease models, functional genomics, and others), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally.

The report offers the value (in USD) for the above segments.

By Component Products
Services
By Application Biomedical
Agriculture
Industrial & Synthetic Biology
By End User Biotechnology & Pharmaceutical Cos.
Academic & Government Institutes
Contract Research / Manufacturing Orgs.
By Technology Type CRISPR-Cas9
Base Editing
Prime Editing
CRISPR-Cas12/13 & Others
By Delivery Method Viral Vectors
Non-viral (LNPs, Electroporation, Nanocarriers)
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
By Component
Products
Services
By Application
Biomedical
Agriculture
Industrial & Synthetic Biology
By End User
Biotechnology & Pharmaceutical Cos.
Academic & Government Institutes
Contract Research / Manufacturing Orgs.
By Technology Type
CRISPR-Cas9
Base Editing
Prime Editing
CRISPR-Cas12/13 & Others
By Delivery Method
Viral Vectors
Non-viral (LNPs, Electroporation, Nanocarriers)
By Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What is the expected value of the CRISPR market in 2030?

The CRISPR market is projected to reach USD 8.95 billion by 2030, growing at a 13.73% CAGR.

Which segment is growing fastest within the CRISPR market?

Agricultural applications hold the highest growth rate, expanding at a 15.45% CAGR through 2030 due to streamlined crop regulations.

Why is prime editing attracting investor attention?

Prime editing delivers precise gene corrections without double-strand breaks, addressing off-target safety concerns and achieving the fastest 16.01% CAGR in the technology segmentation.

How significant is Asia-Pacific to future CRISPR market expansion?

Asia-Pacific records a 16.23% CAGR and benefits from strong governmental backing in China and innovation programs in Japan, making it the quickest-growing regional market.

What are the main barriers to widespread CRISPR therapeutic use?

Off-target safety concerns and high manufacturing costs constitute the primary restraints, reducing the projected CAGR by 2.4% and 1.8%, respectively.

Page last updated on: June 22, 2025

CRISPR And CRISPR-associated (Cas) Genes Market Report Snapshots